Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
54.14
-0.57 (-1.04%)
Official Closing Price
Updated: 7:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
November 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
October 31, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
October 31, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
October 28, 2024
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
October 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
September 30, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
September 25, 2024
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?
Via
MarketBeat
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
September 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
September 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
September 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 10, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
September 09, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
September 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
September 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
August 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
August 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
August 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
August 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
MarketBeat Week in Review – 7/29 - 8/2
August 03, 2024
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Pharma Giant's Shares Up After Impressive Q2 Earnings Release
July 29, 2024
Bristol-Myers Squibb shares were up big on the day of its earnings release. The company beat adjusted EPS estimates and saw strong growth from many drugs.
Via
MarketBeat
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
July 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
July 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
July 08, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
June 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.